Recital 34, Regulation (EU) 2025/787

In forcesince 24 Apr 2025

The supplementary dossiers for the renewal of the approval of the active substances 1,4-dimethylnaphthalene, halauxifen-methyl, propyzamide and sulfoxaflor were submitted via the central submission system on 24 June 2022, 28 July 2022, 27 June 2022 and 11 August 2022 respectively, and the rapporteur Member States are still in the process of assessing the admissibility of the applications for the renewal of the approval of each of those active substances. The applications for the renewal of the approval of the active substances bentazone, bixafen, fluxapyroxad, and sedaxane have been made public by the Authority pursuant to Article 10 of Implementing Regulation (EU) 2020/1740. For all those active substances, the risk assessment pursuant to Article 11 of Implementing Regulation (EU) 2020/1740 has, therefore, not yet been finalised by the respective rapporteur Member States and additional time is needed to complete the remaining steps in each renewal procedure.